Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, T-Cell, Cutaneous 4Neoplasms 3Lymphoma, T-Cell, Peripheral 3Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, B-Cell 2Recurrence 1Neoplasms by Histologic Type 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Rituximab 43Cyclophosphamide 26fludarabine 15ibrutinib 14Vincristine 11Prednisone 11Doxorubicin 11pirtobrutinib 10Bendamustine Hydrochloride 10obinutuzumab 9polatuzumab vedotin 6Inotuzumab Ozogamicin 6tocilizumab 5pembrolizumab 5glofitamab 5Gemcitabine 5zanubrutinib 4venetoclax 4ublituximab 4Lenalidomide 4Brentuximab Vedotin 4Antigens, CD19 4tazemetostat 3acalabrutinib 3Everolimus 3DTRMWXHS-12 3veltuzumab 2sepantronium 2iberdomide 2denileukin diftitox 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, B-Cell × denileukin diftitox × Clear all
NCT00051025 2012-07-13

Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)

Eisai Inc.

Phase 2 Completed
9 enrolled 10 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT00211276 2012-03-14

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

Eisai Inc.

Phase 2 Completed
50 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡